LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Inicio・Lista de Acciones・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Cerrado

SectorSanidad

7.62 -0.13

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

7.55

Máximo

7.62

Métricas clave
By Trading Economics
Ingresos	5.1M 5.1M
Ventas	18M 163M
Margen de beneficios	3.113
Empleados	580
EBITDA	7.2M 28M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+129.36% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-172M 1.7B
Apertura anterior	7.75
Cierre anterior	7.62

Noticias sobre sentimiento de mercado

By Acuity

50%

132 / 371 Clasificación en Healthcare

BioCryst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 sept 2025, 18:25 UTC

Principales Movimientos del Mercado

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27 sept 2025, 07:00 UTC

Ganancias

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27 sept 2025, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

26 sept 2025, 21:56 UTC

Adquisiciones, fusiones, absorciones

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 sept 2025, 20:54 UTC

Ganancias

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 sept 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

26 sept 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

26 sept 2025, 19:54 UTC

Charlas de Mercado

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 sept 2025, 19:53 UTC

Adquisiciones, fusiones, absorciones

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 sept 2025, 19:40 UTC

Ganancias

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 sept 2025, 19:24 UTC

Charlas de Mercado

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 sept 2025, 19:17 UTC

Charlas de Mercado

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 sept 2025, 19:15 UTC

Charlas de Mercado

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 sept 2025, 19:03 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

26 sept 2025, 19:03 UTC

Charlas de Mercado

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 sept 2025, 18:50 UTC

Charlas de Mercado

Ganancias

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 sept 2025, 18:36 UTC

Charlas de Mercado

Silver Closes Out Week With Strong Surge -- Market Talk

26 sept 2025, 18:02 UTC

Adquisiciones, fusiones, absorciones

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 sept 2025, 18:02 UTC

Adquisiciones, fusiones, absorciones

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 sept 2025, 18:02 UTC

Adquisiciones, fusiones, absorciones

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 sept 2025, 17:54 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 sept 2025, 16:56 UTC

Charlas de Mercado

Ganancias

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 sept 2025, 16:41 UTC

Charlas de Mercado

Ganancias

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 sept 2025, 16:26 UTC

Ganancias

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 sept 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

26 sept 2025, 16:12 UTC

Charlas de Mercado

Nike Stock Seen With Limited Upside -- Market Talk

26 sept 2025, 15:59 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

26 sept 2025, 15:59 UTC

Charlas de Mercado

Nike Seen Showing Progress in Turnaround -- Market Talk

Comparación entre iguales

Cambio de precio

BioCryst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

129.36% repunte

Estimación a 12 Meses

Media 17.5 USD 129.36%

Máximo 30 USD

Mínimo 12 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

132 / 371 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.